Glutamine is considered an essential amino acid during stress and critical illness. Parenteral glutamine supplementation in critically ill patients has been shown to improve survival rate and minimise infectious complications, costs and hospital length-of-stay. However, glutamine supplementation in patients receiving enteral nutrition and the best method of administration are still controversial. The purpose of this article is to provide a narrative review of the current evidence and trials of enteral and parenteral glutamine supplementation in multiple trauma patients.
Multiple traumas are life-threatening, not only from the initial insult itself but also from the subsequent extensive immunological impairment and metabolic dysfunction 1 . Major trauma is characterised by alteration and depression of the immune response 2,3 , which is associated with an elevated rate of infectious complications, sepsis, multiple organ failure and death 4, 5 . In fact, the prevalence of infectious complications in critically ill patients continues to be a serious problem and is independently associated with higher rates of hospital mortality 6 .
The role and effectiveness of glutamine supplementation in critically ill patients has been extensively studied and debated in literature for at least the 15 years. A number of systematic reviews and metaanalyses have shed light on this interesting topic [7] [8] [9] . Some of these reviews grouped critically ill patients with surgical patients; the latest considered them as separate groups. The critically ill patient population is haemodynamically and immunologically different from the surgical population. Furthermore, the critically ill patient population is clinically heterogeneous, hence results from one subgroup of patients cannot be generalised to the whole population, even in nutrition support interventions.
Many of the studies that have investigated the effect of intravenous or enteral glutamine supplementation includes multiple trauma patients with other critically ill patients as one population group and have utilised many different outcome measures, not all of which are likely to be of clinical relevance. As the heterogeneity of published trials would have limited the usefulness of a standard meta-analysis approach, and the large outcome measures in these trials made it difficult to pool effect sizes, we decided to undertake a narrative review. Therefore, the purpose of this narrative review was to focus on the trials conducted specifically to investigate theeffect of glutamine or glutamine dipeptide as a single pharmaconutrient in adult multiple trauma patients, including head injury patients, and develop recommendations for future perspectives on glutamine supplementation in this homogeneous group of patients.
Search strategy and selection criteria
The patient group in this review represents the critically ill patients with multiple trauma that require enteral or parenteral nutrition support. Searches on PubMed and EMBASE from 1990 to 2011 were used to identify trials that evaluated enteral and parenteral glutamine supplementation in trauma patients. Search terms included "glutamine", "alanylglutamine", "trauma", "injury" or "head injury". only English language papers were reviewed. Search parameters were limited to human clinical trials. Studies in which glutamine was used in combination with other immunonutrients and safety trials were excluded. Additional articles were identified through searching the bibliography of practice guidelines, systematic reviews and meta-analyses of glutamine supplementation in critically ill patients.
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Immune and metabolic response to trauma and injury
Multiple trauma and severe injury evoke reproducible immune and metabolic responses that correlate with the extent and duration of the injury. The immune (inflammatory) response starts within minutes and is characterised by increased release of pro-inflammatory cytokines. In parallel, there is a concurrent production of anti-inflammatory cytokines. This response is required to restore homeostasis as soon as possible 10 . In uncomplicated trauma and injury, there is an equilibrium between the pro and anti-inflammatory cytokines. However, if the pro-inflammatory mediators predominate, this results in a systemic inflammatory response syndrome. Alternatively, if the anti-inflammatory mediators predominate, this results in compensatory antiinflammatory response syndrome 10 . An imbalance between systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome, depending on the severity and duration of the trauma and stress, may be responsible for increased susceptibility to infectious complications, multiple organ dysfunction syndrome and multiple organ failure, which are associated with a higher mortality rate 11,12 . In conjunction, there is an escalated production of catabolic and counter-regulatory hormones 13 . These neuroendocrine changes trigger the metabolic response that is characterised by hypermetabolism 14 , insulin resistance associated with hyperglycaemia 15 , increased fat breakdown (lypolysis) 16 and accelerated protein catabolism (proteolysis) 14, 17, 18 . Proteolysis, which may reach up to 16%, is mainly derived from the skeletal muscle and can last for up to 21 days 14, 18 . There is also an increase in the rate of protein synthesis, but this does not match the increased rate of proteolysis. Indeed, in critically ill patients, protein catabolism is elevated despite aggressive nutritional support and increased protein intake 19, 20 . Although muscle catabolism is important for providing substrates for acute phase protein synthesis and gluconeogenesis in the liver, severe and prolonged depletion of lean body mass has deleterious effects such as irreversible muscle wastage, impaired wound healing and delayed recovery from illness 21 . Protein catabolism is also associated with the release of glutamine from the skeletal muscle and this results in a marked and prolonged depletion of glutamine levels in plasma and the skeletal muscle 17, 22 .
Glutamine metabolism during stress and critical illness
Glutamine is the most abundant amino acid in the body and is synthesised in sufficient amounts under normal physiological conditions, and therefore has been considered as a non-essential amino acid for decades. It is involved in a wide range of metabolic and biochemical processes in the body [23] [24] [25] [26] . These functions are summarised in Table 1 .
As the preferred fuel for enterocytes, it has been suggested that glutamine may have a role in reducing bacterial translocation across the gastrointestinal tract and thus reduce the risk of infections and sepsis 37 . In fact, enteral glutamine administration has been associated with reduced intestinal permeability and bacterial translocation in some animal studies 38, 39 . Also, some clinical trials showed that glutamine supplementation maintained gastrointestinal structure in critically ill patients and was associated with reduced intestinal permeability 40, 21 . However, other trials could not reproduce this finding 42 . table 1 Glutamine functions in the human body [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Nitrogen transport Acid-base homeostasis Under catabolic conditions, such as critical illness, glutamine is released from the skeletal muscle in large quantities 43 . Although glutamine synthesis is not impaired during critical illness, plasma and intramuscular glutamine levels are severely depleted in conditions 22, 44 such as major surgery 45 , burn injury 46, 47 and multiple trauma 24, 48, 49 because of increased demand. Therefore, glutamine has been proposed as an essential amino acid in these situations 50 .
Clinical trials of glutamine supplementation in multiple trauma patients A number of trials have been conducted to investigate the effect of glutamine supplementation in a homogeneous group of multiple trauma patients. Table 2 and 3 summarise the trials of enteral and parenteral glutamine supplementation in trauma patients, which are subsequently discussed.
Clinical trials of enteral glutamine supplementation in multiple trauma patients
The benefits of glutamine supplementation in patients receiving enteral nutrition and the best route of administration are still controversial. Research indicates that initiation of early enteral nutrition (i.e. within the first 24-48 hours following intensive care unit admission) in critically ill patients, including trauma patients, is recommended when the gastrointestinal tract is functioning as it is associated with decreased infectious morbidity, hospital lengthof-stay and improved overall clinical outcome [51] [52] [53] [54] [55] [56] . Therefore, the concept of enteral glutamine supplementation in multiple trauma patients is attractive and advocated when enteral nutrition is required 57 . However, it has been documented that the systemic bioavailability of glutamine through the enteral route is lower than the parenteral route 30 . Most enterally administered glutamine is utilised and oxidised by the splanchnic organs [58] [59] [60] . Furthermore, before considering glutamine supplementation via the enteral route, it is important to recognise that most enteral trials failed to reach the target prescribed dose due to delayed feeding, feeding intolerance and interruption of feeding due to extubation or surgery 61, 62 .
one of the early trials that have been conducted to investigate the effect of enteral glutamine supplementation in 30 trauma patients by Long et al 63 found that there were no significant differences in outcomes including nitrogen balance, protein synthesis and breakdown, and muscle proteolysis between the glutamine supplemented and the control groups. Also, glucose turnover, oxidation and recycling were not significantly different between the two groups. The same trial attempted to see the effect of glutamine supplementation on hypoaminoacidaemia 64 , which results in an increased concentration of essential amino acids and a decrease in nonessential amino acids in the intracellular pool. However, it was reported that total essential amino acids concentration was significantly increased in both groups, while the nonessential amino acids concentration was increased significantly only in the control group. This increase was explained by the added amino acids to the control formula to make it isonitrogenous. Plasma glutamine level was not influenced by supplementation. These results suggested that a short period of glutamine provision (i.e. three days) has no effect on nutritional or metabolic outcomes and a longer period is required. The authors explained the negative results by altered glutamine absorption in critically ill patients and glutamine being mostly oxidised by the gut and liver [58] [59] [60] . on the other hand, Houdik et al showed that enteral glutamine supplementation significantly increased plasma glutamine concentration, which was associated with an increased plasma arginine concentration suggesting that enteral glutamine stimulated renal production of arginine 65 .
Mortality as a primary outcome was investigated in one of the largest trials of enteral glutamine supplementation in trauma patients 66 . The in-hospital mortality rate was higher in the treatment group compared with the control group, but the results were not significant (P=0.09), particularly after controlling for age and severity of illness (P ≤0.11). This trial suggested that enteral glutamine might have negative effects with a trend toward increased mortality. The authors theorised that enteral administration of glutamine makes it available to the bacteria in the gastrointestinal tract 67 .
The effect of enteral glutamine supplementation on infectious morbidity was investigated in two main trials 65, 68 . Houdijk and colleagues 65 reported that glutamine-enriched enteral feed resulted in a significant decrease in pneumonia (17 vs 45%; P <0.02), bacteraemia (7 vs 42%; P <0.005) and sepsis (4 vs 26%; P <0.02). Gram-negative bacteraemia occurred in 54% of the cases of bacteraemia in the control patients and was not reported in any of the glutamine supplemented patients, suggesting that glutamine might prevent bacterial translocation from the gut. In contrast, Schulman et al 68 found that enteral glutamine had no significant effect on reducing infectious complications and the use of antibiotics. In both trials there were no significant differences in mechanical ventilation days, intensive care unit and hospital length-of-stay between the supplemented and the control groups.
In an attempt to explain the relationship between the reduction in infectious morbidity by enteral glutamine supplementation and endocrine responses, Houdijk et al reported in a subsequent paper 69 that enteral glutamine had no influence on metabolic and endocrine changes in trauma patients. Hyperglycaemia was sustained in both glutamine and control groups, and plasma levels of stress hormones (cortisol and glucagon) increased to high normal levels in both groups, but this was not significant. Growth hormone levels were within the normal range and did not differ between groups. In both groups there was a significant increase in α1-antitrypsin levels and the inflammatory marker C-reactive protein.
It was concluded that the reduction in infectious complications by glutamine supplementation was not related to the changes in the metabolic and hormonal responses.
It has been reported by Boelens et al 24 , as part of the trial by Houdijk et al 65 , that glutamine-enriched enteral nutrition can restore and modulate immune function. It investigated the effect of glutamine supplemented enteral nutrition versus isocaloric, isonitrogenous enteral nutrition on human leukocyte antigen (HLA)-DR and Fc receptor (FcγRI/CD64) expression on monocytes which are severely depleted in trauma patients 4, 70 . Both groups' results were compared with healthy volunteers. As expected, HLA-DR expression was much lower in both groups compared to the healthy volunteers. However, glutamine-enriched enteral nutrition resulted in significantly increased expression of HLA-DR but still did not restore normal values. There was no difference in the FcγRI/CD64 expression between both groups and the healthy volunteers. It was concluded that glutamine had beneficial effects on increasing HLA-DR expression and thus improving cellular immune function and this may play a role in reducing infectious complications in trauma patients.
In a pilot study, 20 patients with severe trauma were randomised to receive enteral glutamine or an isonitrogenous placebo during the first 24 hours of resuscitation, before even starting enteral feeding for ten days 71 . The supplementation was given as a bolus two to three times daily, dissociated from enteral feed as a pharmacological dose. The study demonstrated that glutamine was well-tolerated during resuscitation with no adverse events. It was reported that the glutamine group had significantly fewer instances of high gastric output (5 vs 23, P=0.01) and abdominal distension (3 vs 12; P=0.021). These results suggested that enteral glutamine can be safely given during active shock resuscitation and enhances gastrointestinal tolerance. However, this was a pilot study and a larger trial is required to investigate the effect of enteral glutamine administered to haemodynamically unstable patients on other clinical outcomes.
Clinical trials of parenteral glutamine supplementation in multiple trauma patients
There are a few trials that have investigated the effect of parenteral glutamine supplementation in trauma patients receiving parenteral nutrition. Limitations of glutamine supplementation via the enteral route triggered researchers to investigate the effect of intravenous glutamine supplementation in patients receiving enteral nutrition.
The effect of parenteral alanyl-glutamine on insulin resistance was investigated by Bakalar et al 32 , who showed significantly improved insulin sensitivity and insulin-mediated glucose disposal in the glutamine supplemented patients. There was no significant difference in the Sequential Organ Failure Assessment score between groups. The rate of protein breakdown was not different between groups during the study, but hypermetabolism was attenuated in the glutamine supplemented patients by reducing energy expenditure. It was concluded that glutamine supplementation was associated with significantly better insulin sensitivity in trauma patients, offering a new approach to glycemic control in this group of patients. The authors concluded that this trial should be considered as a pilot study and further trials are required to gain further understanding about the mechanisms by which glutamine improves insulin resistance.
The effect of intravenous alanyl-glutamine supplementation in 46 patients with severe traumatic brain injury receiving total parenteral nutrition was investigated in a randomised trial 72 . The authors demonstrated that alanyl-glutamine supplementation resulted in a significant decrease in infectious complications (P <0.05). It was reported that glutamine supplementation was associated with a significant decrease in two-week mortality rate and alimentary tract haemorrhage (P <0.05). There was a significantly shorter intensive care unit length-of-stay with glutamine supplementation (P <0.05). This study was the first to investigate the effects of glutamine supplementation in head injury patients. However, there are number of limitations of this paper. First, in terms of a standard basic treatment protocol, no stress ulcer prevention was provided, which is not an accepted standard management 73 . The main cause of death in the second week (six patients in the control group versus one in the glutamine group) was uncontrolled alimentary tract haemorrhage, which is not common in head injury patients and is potentially related to lack of stress ulcer prevention. The results suggest that glutamine might play a role in prevention of alimentary tract haemorrhage but only if patients are not receiving standard management (i.e. stress ulcer prevention). Furthermore, this was a single trial and the number of recruited patients was relatively small, limiting the ability to make clear conclusions and recommendations. It is also important to mention that the dose used was relatively low (2 mg/kg) compared with other trials that found beneficial effects.
There is no evidence for beneficial effects of intravenous glutamine supplementation in trauma patients receiving enteral nutrition. However, in a pilot, randomised, double-blind trial, Eroglu 74 investigated the effect of intravenous supplementation of alanyl-glutamine in 40 severe trauma patients receiving enteral nutrition. It was reported that total plasma glutathione levels increased significantly in the glutamine group on day 7 and 10 (P <0.001). As reported by the author, the limitations of this trial were the small number of recruited patients and the short follow-up period.
The effect of parenteral glutamine on toll-like receptors (TLR2 and TLR4), which are key receptors sensing infections, was investigated in a singleblind, randomised trial in trauma patients receiving parenteral nutrition 75 . It was reported that the expression levels of TLR2 on monocytes were similar between groups before and after supplementation. There was also no significant difference in TLR4 levels between groups before and after treatment. Although the study was not powered to investigate the clinical effect of glutamine on reducing infectious complications, there was a decreased incidence of infections and hospital length-of-stay in the glutamine group, which did not reach significance. It was concluded that glutamine-supplemented parenteral nutrition in trauma patients had no influence on the expression or functionality of TLRs on monocytes.
In summary, from the previous trials, positive and consistent findings were demonstrated in patients receiving glutamine-supplemented parenteral nutrition and with higher doses.
Limitation of glutamine trials in multiple trauma patients
Like other nutritional interventions, there are limitations in the existing trials of glutamine supplementation in trauma patients that make recommendations inconclusive. These are as follows:
• The quality of many trials was low and did not meet the CoNSoRT (consolidated standards of reporting trials) guidelines 76, 77 in terms of random allocation concealment, blinding of assessors or care-givers and presenting results in an intentionto-treat analysis. • Most trials had a small number of subjects and were not sufficiently powered to investigate major clinical outcomes such as mortality [78] [79] [80] .
• The doses varied between trials which makes clear comparison between trials problematic. • Some trials used a mixture of immunonutrients concurrently as an intervention 81, 82 , which makes it impossible to make a clear judgment about the exact beneficial effect of each nutrient. • other trials used a historical group as a control 57 .
• In enteral feeding it is often difficult to deliver the supplemented feed effectively due to feeding intolerance, which is present in many critically ill patients 63, 65 . • The period of supplementation was very short in some trials (e.g. three to seven days) 32, 63, 74, 83 . These limitations were also highlighted in a European roundtable 84 . As mentioned earlier, some recent trials gave the enteral supplementation as a separate supplementation and not as part of the enteral feeding formula 81 . others investigated the effect of intravenous supplementation in patients receiving enteral feeds 74 . This represents an advance from the traditional 'immunonutrition' paradigm to a new 'pharmaconutrition' one [85] [86] [87] .
CoNCLUSIoN
While there is emerging evidence that glutamine supplementation should be considered as a potential therapeutic regimen in patients with multiple trauma, adequately powered, multi-centre well-designed trials are needed to provide robust clinical evidence. The trials that have been conducted in homogeneous trauma patients are limited and the results are inconclusive. Due to the difficulty and uncertainty of enteral supplementation of glutamine in patients receiving enteral nutrition, future trials should focus on delivering glutamine intravenously to these patients. Investigating significant outcome measures such as mortality, organ dysfunction and infectious complications, rather than short-term surrogate measures, are also required.
